TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01325493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
Study: NCT01953315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Muscle Progenitor Cells
Description: Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
Study: NCT03025581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nipple stimulation
Description: For the intervention group participants will be instructed to gently massage alternate breasts, especially around the nipples for 15 minutes every 6 hours until the appearance of regular contractions but not more than 24 hours. Moist cloth or lubricating or moisturizing cream will be offered to facilitate the procedure according to individual preferences. In the control group all participants will be asked to avoid any breast stimulation during the study period.
Study: NCT02604966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate (AS) group
Description: Oral treatment with AS at 4mg/kg/day for 3 days followed by three days of DHA - PPQ in order to insure total parasite clearance. Randomization is done by blocks of ten.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA - PPQ group
Description: Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
Study: NCT03669133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Vitamin E 800 IU/daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo daily
Study: NCT02280811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patients will receive Fludarabine 25 mg/m\^2/day for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E6 TCR
Description: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
Study: NCT04300725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Counseling
Description: Patients in the other study arm receive verbal + video counseling prior to their induction of labor.
Study: NCT01210443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxentan
Description: sitaxentan sodium 100 mg
Study: NCT04103918

Intervention type: DEVICE
Group type: OTHER
Intervention: Jalucomplex
Description: Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
Study: NCT00770861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets , oral administration Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets, oral administration
Study: NCT03619122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second Examination
Description: The colonoscopy is passed to the cecum and then withdrawn to hepatic flexure. Then, the scopy is inserted to the cecum and withdrawn to hepatic flexure again for second foreard view examination.
Study: NCT03229577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga
Description: Yoga-based breathing program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Mindfulness program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Intelligence
Description: Emotional Intelligence program.
Study: NCT03899740

Intervention type: OTHER
Intervention: Brainstorming 1
Description: Expert recommendation statements will be collected for peer evaluation.

Intervention type: OTHER
Intervention: Ranking - Round 1
Description: Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.

Intervention type: OTHER
Intervention: Ranking - Round 2
Description: Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
Study: NCT04690647

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Opioid and non opioid postoperative analgesia.
Description: Postoperative analgesia will be based on opioid and non opioid analgesics according to standardised protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid and non opioid postoperative analgesia.
Description: Postoperative analgesia will be based on opioid and non opioid analgesics according to standardised protocol.
Study: NCT03899740

Intervention type: OTHER
Intervention: Ranking - Round 3
Description: Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
Study: NCT01872351

Intervention type: DRUG
Intervention: Nutraceuticals
Study: NCT01570491

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided spinal anesthesia
Description: ultrasound-guided technique for block placement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard spinal anesthesia
Description: Anesthesiologist will use standard technique for placement of spinal block.
Study: NCT01412242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensive search for isolated calf DVT
Description: Extensive search for isolated calf DVT in patients with negative CUS of the proximal veins who have a high PTP and a positive D-dimer
Study: NCT04690647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid and non opioid postoperative analgesia.
Description: Postoperative analgesia will be based on opioid and non opioid analgesics according to standardised protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block
Description: Ultrasound guided suprainguinal fascia iliaca compartment block will be performed using 0.375% ropivacaine and 5ug/ml adrenaline according to standardised protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block
Description: Ultrasound guided suprainguinal fascia iliaca compartment block will be performed using 0.375% ropivacaine and 5ug/ml adrenaline according to standardised protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered preoperatively in a dose of 0,1 mg/kg.
Study: NCT02844608

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaires
Description: Patients will be asked to complete standardized HRQoL questionnaires: the EORTC QLQ-C30 with its specific module by cancer site (QLQ-BR23, QLQ-CR29, QLQ-LC13) at first visit before starting treatment and then before every medical consultation during four months.
Study: NCT00668967

Intervention type: DRUG
Group type: OTHER
Intervention: verapamil
Description: 240 mg extended release tablets once daily at bedtime for 28 days

Intervention type: DRUG
Group type: OTHER
Intervention: verapamil
Description: 240 mg extended release tablets once daily at bedtime for 28 days
Study: NCT01905735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhustoxicodendron 30
Description: 1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.
Study: NCT02572713

Intervention type: PROCEDURE
Intervention: Biofluid samplings
Description: Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)
Study: NCT01522495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)
Description: Intravenous(1X) in conjunction with SPY Imaging (1 arm)
Study: NCT02572713

Intervention type: PROCEDURE
Intervention: Biofluid samplings
Description: Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)

Intervention type: PROCEDURE
Intervention: Biofluid samplings
Description: Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)

Intervention type: PROCEDURE
Intervention: Biofluid samplings
Description: Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)

Intervention type: PROCEDURE
Intervention: Tissue samplings
Description: Tissue samplings (skin, colon, submandibular gland)

Intervention type: PROCEDURE
Intervention: Tissue samplings
Description: Tissue samplings (skin, colon, submandibular gland)

Intervention type: PROCEDURE
Intervention: Tissue samplings
Description: Tissue samplings (skin, colon, submandibular gland)

Intervention type: PROCEDURE
Intervention: Tissue samplings
Description: Tissue samplings (skin, colon, submandibular gland)

Intervention type: DRUG
Intervention: DaTSCAN™

Intervention type: DRUG
Intervention: DaTSCAN™

Intervention type: DRUG
Intervention: DaTSCAN™

Intervention type: DRUG
Intervention: DaTSCAN™
Study: NCT00674882

Intervention type: OTHER
Intervention: Data Collection
Description: Data Collection, Outcomes Research, Statistical Data Analysis, Longitudinal Study
Study: NCT04163991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: liquid for IV infusion following dilution in normal saline
Study: NCT03962439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Demand Photography
Description: The high-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured high-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Demand Photography
Description: The moderate-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured moderate-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: At-Home Engagement
Description: The placebo control group will engage, alone at home, in tasks that are relatively low in intellectual engagement such as listening to music and radio or completing work-books that rely primarily on activation of knowledge.
Study: NCT00984022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Type of dressing - Iodoform
Description: Dressing for packing a cutaneous abscess

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Type of dressing - Aquacel
Description: Aquacel dressing
Study: NCT02771353

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WT_vDIBH

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: VMAT_FB
Study: NCT02648438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 Solution for infusion (150 μg intravenous formulation)
Description: Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 Solution for infusion (150 μg intravenous formulation)
Description: Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 Oral suspension (1200 μg oral formulation)
Description: 0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 Oral suspension (1200 μg oral formulation)
Description: 0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)
Description: Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)
Description: Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)
Description: Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 Pressurized inhalation suspension (400 μg) by pMDI
Description: Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg
Study: NCT01131637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNRG-1
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection
Study: NCT01443195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron preparation
Description: Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal. Serum samples will be obtained at 3 different times:~1. Before starting iron supplementation (maximum one week before).~2. At the beginning of iron supplementation in order to assess early signs of erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).~3. Before discharge from hospitalization in order to asses the iron metabolism and sings of iron deficiency (At least more than 2 weeks of supplementation).
Study: NCT02653664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PsychoEducation
Description: Condition #1

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Hypnosis Training
Description: Condition #2

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Condition #3
Study: NCT04005638

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: 45 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Intervention type: BIOLOGICAL
Intervention: urine sample
Description: 12 ml
Study: NCT00848536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution
Description: One drop once daily in the evening for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 0.004% (BAK-preserved) Eye Drops, Solution
Description: One drop once daily in the evening for 3 months
Study: NCT02435160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Study: NCT00365365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide (AC) + bevacizumab
Description: For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 60 mg/m\^2 IV push or infusion followed by cyclophosphamide 600 mg/m\^2 IV push or infusion~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (T) + bevacizumab
Description: For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel 100 mg/m\^2 IV~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy~Note: The starting dose of docetaxel was reduced to 75 mg/m\^2 if toxicity occurred that met the criteria for doxorubicin dose reduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab
Description: For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 50 mg/m\^2 IV push or infusion followed by cyclophosphamide 500 mg/m\^2 IV push or infusion followed by docetaxel 75 mg/m\^2~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab
Description: For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel in 75 mg/m\^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by~* trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2)~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and trastuzumab maintenance therapy
Description: * bevacizumab 15 mg/kg was infused IV followed by~* trastuzumab 6 mg/kg IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab maintenance therapy
Description: - bevacizumab 15 mg/kg was infused IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab maintenance therapy
Description: - bevacizumab 15 mg/kg was infused IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.
Study: NCT02511535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBE booster vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBE booster vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TBE booster vaccination
Study: NCT04343794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOVITALS
Description: Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period
Study: NCT02942563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle for 4-6 cycles,~Chemoradiation for patients who are not suitable to surgery:~Pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/m², bid po, d1-5, qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus Capecitabine 1.0/m² bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME.~All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy after TME.
Study: NCT02267187

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Grafting
Description: Fat Grafting is a procedure that involves moving a person's own fat from an area of the body where it is less needed to another area of the body to improve its appearance. The fat is usually taken from the thighs or abdomen with a small liposuction tube and then moved to an area that has lost volume or fullness due to aging, trauma, surgery, birth defects, or other causes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Description: A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coleman Cannulas
Description: The plastic surgeon, will use small narrow tube-like instruments called cannulas, will remove fat from various places throughout the body (commonly the abdomen and thighs). The plastic surgeon will then use the Coleman cannulas (specialized smaller cannulas with varied shapes and tip sizes specifically made to deliver smaller amounts of fat) to fill the desired area.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tefla non-adherent gauze pad
Description: The processing of the fat graft material is done using a Tefla non-adherent gauze pad in a rolling technique that separates the aqueous and oil layers from the injected component.
Study: NCT01609387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fit For me
Study: NCT01609387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fit For me

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fit For me
Study: NCT04050709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: PD-L1 t-haNK Suspension for Infusion
Study: NCT01522495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)
Description: Intravenous(1X) in conjunction with SPY Imaging (1 arm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)
Description: Intravenous(1X) in conjunction with SPY Imaging (1 arm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Imaging
Description: SPY Imaging to assess tissue perfusion
Study: NCT01609387

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Davitamon

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Davitamon

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Davitamon
Study: NCT01746875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 2.0 mg monthly x 3 doses, then as needed based on recurrence of activity on OCT. If no effect after the initial 3 doses; 2.0 mg monthly x 3 doses is repeated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: given if aflibercept does not have any effect. Verteporfin photodynamic therapy is given in combination with aflibercept and triamcinolone. The treatment can be repeated after 3 month.